Research paper

The ProVIDe study: the impact of protein intravenous nutrition on development in extremely low birthweight babies

BMC Pediatrics

Aug 2015

DOI: 10.1186/s12887-015-0411-y

Citations: 23

Influential: 0

Interventional (Human) Studies

COI

Study answer

What this study found

No outcome results were provided in the source packet. The study was designed to test whether extra early intravenous protein during the first 5 days after birth improves survival free from neurodevelopmental disability at 2 years' corrected age in extremely low birthweight infants, with additional evaluation of growth, body composition, neonatal morbidity, and nutritional intake. The authors' stated premise was that positive findings could support a simple, low-cost change in neonatal nutrition practice.

Study & population: Multicentre randomized 1:1 trial in extremely low birthweight preterm infants with birthweight <1000 g and a functioning umbilical arterial catheter.
Intervention: The active regimen was an intravenous amino acid infusion using 8.5% TrophAmine® delivered through the umbilical arterial catheter at 0.5 mL/h for 120 h after birth.
Key limitation: The source packet provides a study rationale and protocol-level details rather than reported efficacy results, so treatment effect cannot be assessed from the available information.

View source

Open PDF

Original abstract

No abstract is available for this paper.